[Spectral properties of hematoporphyrin derivative after interacted with human serum albumin].
The spectral properties of photosensitizer HpD, human serum albumin (HSA) and their complex have been studied. The results show that HpD can form HpD-HSA complex with HSA in physiological condition. Compared with pure HpD, the maximum absorption and the fluorescence peaks for HpD-HSA complex had 8-10 nm red-shift. When HpD-HSA complex was excited by the light of corresponding to excitation peaks of HSA (228 and 279 nm) and HpD (394 nm), it was found that the absorption of HSA and HpD both contributed to the emission of HpD-HSA complex at 622 nm. The complex of HpD-HSA was individually excited by wavelengths corresponding to HpD absorption peaks of 402, 502, 537 and 570 nm, and the excitation efficiency of HpD-HSA at pumping wavelength of 537 and 570 nm was higher than that of HpD. The results demonstrate that the red-shift caused by the interaction of HpD and the special proteins in blood should be considered in selecting the excitation and emission wavelength in photodynamic diagnosis and therapy. The results also indicate that the excitation efficiency of porphyrin-protein complex in vivo is higher than that of HpD in vitro when a longer wavelength light corresponding to the week absorption peaks of porphyrin-protein complex is used in photodynamic therapy.
Wu
Yun-xia
YX
Institute of Laser Life Science, South China Normal University, Guangzhou 510631, China.
Xing
Da
D
D017324:Hematoporphyrin Derivative / Q000032:analysis* / Q000737:chemistry; D006801:Humans; D017319:Photosensitizing Agents / Q000032:analysis* / Q000737:chemistry; D012709:Serum Albumin / Q000737:chemistry*; D013050:Spectrometry, Fluorescence / Q000379:methods*; D013053:Spectrophotometry / Q000379:methods*
D017319:Photosensitizing Agents; D012709:Serum Albumin; D017324:Hematoporphyrin Derivative